Beyond our oncology and CNS therapeutic focus, we also have one programme in inflammation, partnered with Verona Pharma
Persistent and poorly treated
A whole spectrum of inflammatory diseases may affect the human body. Some of these conditions are well understood and well-treated, but many are not. Unmet medical need and significant market potential mean that this is another priority pipeline asset we are determined to exploit to the full.